Do analysts prefer BCTX or TLSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better earnings & valuation, BCTX or TLSA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Briacell Therap N/A N/A -$26.31M -$7.92 N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Is BCTX or TLSA more profitable?

Tiziana Life Sciences' return on equity of 0.00% beat Briacell Therap's return on equity. Company Net Margins Return on Equity Return on Assets Briacell Therap N/A -153.53% -129.26% Tiziana Life Sciences N/A N/A N/A

Does the media prefer BCTX or TLSA?

In the previous week, Tiziana Life Sciences had 1 more articles in the media than Briacell Therap. MarketBeat recorded 2 mentions for Tiziana Life Sciences and 1 mentions for Briacell Therap. Briacell Therap's average media sentiment score of 0.00 equaled Tiziana Life Sciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Briacell Therap 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tiziana Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is INO or BCTX more profitable?

Briacell Therap's return on equity of -153.53% beat Inovio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Inovio Pharmaceuticals N/A -669.94% -73.97% Briacell Therap N/A -153.53% -129.26%

Does the media refer more to INO or BCTX?

In the previous week, Inovio Pharmaceuticals had 1 more articles in the media than Briacell Therap. MarketBeat recorded 2 mentions for Inovio Pharmaceuticals and 1 mentions for Briacell Therap. Inovio Pharmaceuticals' average media sentiment score of 1.00 beat Briacell Therap's score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inovio Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Briacell Therap 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer BCTX or PMN?

Promis Neurosciences has a consensus target price of $34.00, indicating a potential upside of 131.37%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, analysts clearly believe Promis Neurosciences is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Promis Neurosciences 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.88

Which has preferable valuation and earnings, BCTX or PMN?

Promis Neurosciences is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Briacell Therap N/A N/A -$26.31M -$7.92 N/A Promis Neurosciences N/A N/A -$39.72M -$8.54 N/A

Is BCTX or PMN more profitable?

Promis Neurosciences' return on equity of -143.09% beat Briacell Therap's return on equity. Company Net Margins Return on Equity Return on Assets Briacell Therap N/A -153.53% -129.26% Promis Neurosciences N/A -143.09% -109.15%

Does the media prefer BCTX or PMN?

In the previous week, Promis Neurosciences had 10 more articles in the media than Briacell Therap. MarketBeat recorded 11 mentions for Promis Neurosciences and 1 mentions for Briacell Therap. Promis Neurosciences' average media sentiment score of 0.44 beat Briacell Therap's score of 0.00 indicating that Promis Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Briacell Therap 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Promis Neurosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BCTX or ADCT?

ADC Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 414.40%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ADC Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Does the media favor BCTX or ADCT?

In the previous week, ADC Therapeutics had 2 more articles in the media than Briacell Therap. MarketBeat recorded 3 mentions for ADC Therapeutics and 1 mentions for Briacell Therap. ADC Therapeutics' average media sentiment score of 0.34 beat Briacell Therap's score of 0.00 indicating that ADC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Briacell Therap 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ADC Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BCTX or CBUS?

Cibus has a consensus target price of $9.00, suggesting a potential upside of 423.26%. Given Cibus' stronger consensus rating and higher possible upside, analysts plainly believe Cibus is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cibus 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BCTX or CBUS more profitable?

Briacell Therap has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Briacell Therap's return on equity of -153.53% beat Cibus' return on equity. Company Net Margins Return on Equity Return on Assets Briacell Therap N/A -153.53% -129.26% Cibus -2,258.89% -287.03% -27.99%

Does the media refer more to BCTX or CBUS?

In the previous week, Cibus had 7 more articles in the media than Briacell Therap. MarketBeat recorded 8 mentions for Cibus and 1 mentions for Briacell Therap. Briacell Therap's average media sentiment score of 0.00 beat Cibus' score of -0.28 indicating that Briacell Therap is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Briacell Therap 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cibus 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Briacell Therap (BCTX) Competitors

$3.50 -0.58 (-14.13%)

As of 02:46 PM Eastern

Compare

BCTX vs. TLSA, INO, PMN, ADCT, and CBUS

Should you buy Briacell Therap stock or one of its competitors? Briacell Therap's main competitors and comparable companies include Tiziana Life Sciences (TLSA), Inovio Pharmaceuticals (INO), Promis Neurosciences (PMN), ADC Therapeutics (ADCT), and Cibus (CBUS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Briacell Therap compare to Tiziana Life Sciences?

Briacell Therap (NASDAQ:BCTX) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

In the previous week, Tiziana Life Sciences had 1 more articles in the media than Briacell Therap. MarketBeat recorded 2 mentions for Tiziana Life Sciences and 1 mentions for Briacell Therap. Briacell Therap's average media sentiment score of 0.00 equaled Tiziana Life Sciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Briacell Therap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tiziana Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tiziana Life Sciences' return on equity of 0.00% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
Tiziana Life Sciences	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

15.4% of Briacell Therap shares are held by institutional investors. 0.7% of Briacell Therap shares are held by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Briacell Therap has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market.

Summary

Tiziana Life Sciences beats Briacell Therap on 6 of the 8 factors compared between the two stocks.

How does Briacell Therap compare to Inovio Pharmaceuticals?

Inovio Pharmaceuticals (NASDAQ:INO) and Briacell Therap (NASDAQ:BCTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Briacell Therap's return on equity of -153.53% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%
Briacell Therap	N/A	-153.53%	-129.26%

26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 15.4% of Briacell Therap shares are held by institutional investors. 1.7% of Inovio Pharmaceuticals shares are held by insiders. Comparatively, 0.7% of Briacell Therap shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Inovio Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market.

Inovio Pharmaceuticals currently has a consensus target price of $3.17, indicating a potential upside of 152.32%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Inovio Pharmaceuticals is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Briacell Therap has lower revenue, but higher earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	2,162.78	-$84.95M	-$0.91	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A

In the previous week, Inovio Pharmaceuticals had 1 more articles in the media than Briacell Therap. MarketBeat recorded 2 mentions for Inovio Pharmaceuticals and 1 mentions for Briacell Therap. Inovio Pharmaceuticals' average media sentiment score of 1.00 beat Briacell Therap's score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Briacell Therap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Inovio Pharmaceuticals beats Briacell Therap on 12 of the 15 factors compared between the two stocks.

How does Briacell Therap compare to Promis Neurosciences?

Briacell Therap (NASDAQ:BCTX) and Promis Neurosciences (NASDAQ:PMN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Promis Neurosciences is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$8.54	N/A

In the previous week, Promis Neurosciences had 10 more articles in the media than Briacell Therap. MarketBeat recorded 11 mentions for Promis Neurosciences and 1 mentions for Briacell Therap. Promis Neurosciences' average media sentiment score of 0.44 beat Briacell Therap's score of 0.00 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Briacell Therap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Promis Neurosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Promis Neurosciences has a consensus target price of $34.00, indicating a potential upside of 131.37%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, analysts clearly believe Promis Neurosciences is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Promis Neurosciences' return on equity of -143.09% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
Promis Neurosciences	N/A	-143.09%	-109.15%

Briacell Therap has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.23, meaning that its share price is 123% less volatile than the broader market.

15.4% of Briacell Therap shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 0.7% of Briacell Therap shares are held by insiders. Comparatively, 1.5% of Promis Neurosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Promis Neurosciences beats Briacell Therap on 10 of the 14 factors compared between the two stocks.

How does Briacell Therap compare to ADC Therapeutics?

Briacell Therap (NASDAQ:BCTX) and ADC Therapeutics (NYSE:ADCT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by company insiders. Comparatively, 5.1% of ADC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Briacell Therap has a net margin of 0.00% compared to ADC Therapeutics' net margin of -121.77%. ADC Therapeutics' return on equity of 0.00% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
ADC Therapeutics	-121.77%	N/A	-32.74%

Briacell Therap has higher earnings, but lower revenue than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
ADC Therapeutics	$79.58M	1.56	-$142.62M	-$0.66	N/A

Briacell Therap has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.89, suggesting that its share price is 89% more volatile than the broader market.

In the previous week, ADC Therapeutics had 2 more articles in the media than Briacell Therap. MarketBeat recorded 3 mentions for ADC Therapeutics and 1 mentions for Briacell Therap. ADC Therapeutics' average media sentiment score of 0.34 beat Briacell Therap's score of 0.00 indicating that ADC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Briacell Therap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADC Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ADC Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 414.40%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

ADC Therapeutics beats Briacell Therap on 12 of the 15 factors compared between the two stocks.

How does Briacell Therap compare to Cibus?

Briacell Therap (NASDAQ:BCTX) and Cibus (NASDAQ:CBUS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

In the previous week, Cibus had 7 more articles in the media than Briacell Therap. MarketBeat recorded 8 mentions for Cibus and 1 mentions for Briacell Therap. Briacell Therap's average media sentiment score of 0.00 beat Cibus' score of -0.28 indicating that Briacell Therap is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Briacell Therap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cibus	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Briacell Therap has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Briacell Therap's return on equity of -153.53% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
Cibus	-2,258.89%	-287.03%	-27.99%

Cibus has a consensus target price of $9.00, suggesting a potential upside of 423.26%. Given Cibus' stronger consensus rating and higher possible upside, analysts plainly believe Cibus is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 33.8% of Cibus shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by company insiders. Comparatively, 29.9% of Cibus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Briacell Therap has higher earnings, but lower revenue than Cibus. Cibus is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
Cibus	$4.35M	30.24	-$127.08M	-$1.65	N/A

Briacell Therap has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market. Comparatively, Cibus has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market.

Summary

Cibus beats Briacell Therap on 10 of the 15 factors compared between the two stocks.

Get Briacell Therap News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCTX vs. The Competition

Export

Metric	Briacell Therap	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$30.39M	$3.99B	$7.28B	$12.72B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-0.44	11.76	271.35	24.06
Price / Sales	N/A	1,302.10	605.78	77.99
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	0.38	17.24	11.18	6.39
Net Income	-$26.31M	-$22.72M	$3.46B	$348.39M
7 Day Performance	3.10%	2.86%	1.95%	1.06%
1 Month Performance	-2.37%	9.66%	7.28%	5.22%
1 Year Performance	-49.92%	54.43%	24.58%	16.09%

Briacell Therap Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCTX Briacell Therap	0.4701 of 5 stars	$3.50 -14.1%	N/A	-41.7%	$30.39M	N/A	N/A	8	News Coverage High Trading Volume
TLSA Tiziana Life Sciences	0.6477 of 5 stars	$1.09 -3.0%	N/A	-44.7%	$136.42M	N/A	N/A	8	News Coverage High Trading Volume
INO Inovio Pharmaceuticals	3.1392 of 5 stars	$1.29 +7.1%	$3.17 +146.4%	-39.8%	$132.87M	$60K	N/A	320	High Trading Volume
PMN Promis Neurosciences	3.2878 of 5 stars	$14.69 -1.9%	$31.50 +114.4%	+8.3%	$131.74M	N/A	N/A	5	Analyst Forecast
ADCT ADC Therapeutics	3.498 of 5 stars	$1.04 +0.5%	$5.00 +383.1%	-68.5%	$131.64M	$81.36M	N/A	310

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCTX) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Briacell Therap (BCTX) Competitors

BCTX vs. TLSA, INO, PMN, ADCT, and CBUS

How does Briacell Therap compare to Tiziana Life Sciences?

Summary

How does Briacell Therap compare to Inovio Pharmaceuticals?

Summary

How does Briacell Therap compare to Promis Neurosciences?

Summary

How does Briacell Therap compare to ADC Therapeutics?

Summary

How does Briacell Therap compare to Cibus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCTX vs. The Competition

Briacell Therap Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Briacell Therap (BCTX) Competitors

BCTX vs. TLSA, INO, PMN, ADCT, and CBUS

How does Briacell Therap compare to Tiziana Life Sciences?

Which has better earnings & valuation, BCTX or TLSA?

Does the media prefer BCTX or TLSA?

Is BCTX or TLSA more profitable?

Do analysts prefer BCTX or TLSA?

Do insiders and institutionals have more ownership in BCTX or TLSA?

Which has more risk & volatility, BCTX or TLSA?

Summary

How does Briacell Therap compare to Inovio Pharmaceuticals?

Is INO or BCTX more profitable?

Do insiders & institutionals believe in INO or BCTX?

Which has more risk and volatility, INO or BCTX?

Do analysts prefer INO or BCTX?

Which has better valuation & earnings, INO or BCTX?

Does the media refer more to INO or BCTX?

Summary

How does Briacell Therap compare to Promis Neurosciences?

Which has preferable valuation and earnings, BCTX or PMN?

Does the media prefer BCTX or PMN?

Do analysts prefer BCTX or PMN?

Is BCTX or PMN more profitable?

Which has more risk & volatility, BCTX or PMN?

Do institutionals & insiders have more ownership in BCTX or PMN?

Summary

How does Briacell Therap compare to ADC Therapeutics?

Do insiders and institutionals have more ownership in BCTX or ADCT?

Is BCTX or ADCT more profitable?

Which has higher earnings & valuation, BCTX or ADCT?

Which has more volatility & risk, BCTX or ADCT?

Does the media favor BCTX or ADCT?

Do analysts recommend BCTX or ADCT?

Summary

How does Briacell Therap compare to Cibus?

Does the media refer more to BCTX or CBUS?

Is BCTX or CBUS more profitable?

Do analysts recommend BCTX or CBUS?

Do institutionals & insiders hold more shares of BCTX or CBUS?

Which has better earnings and valuation, BCTX or CBUS?

Which has more risk and volatility, BCTX or CBUS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCTX vs. The Competition

Briacell Therap Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools